GlassScriptPhysician profile
Eric M Peterson
NPI 1710955877
$2,004.11
in general payments reported to CMS, 2019-2025
25 companies · $24.79 in 2025
The $24.79 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $200 · 2021: $153 · 2022: $431 · 2023: $331 · 2024: $75.74 · 2025: $24.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $431.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $268.82 | 2019-2023 | |
| Novo Nordisk INC | $238.98 | 2019-2023 | Wegovy |
| Amgen INC. | $228.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.60 | 2019-2023 | Jardiance |
| Astellas Pharma US INC | $153.65 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $136.20 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $106.32 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Sanofi-Aventis U.S. LLC | $105.16 | 2019-2023 | |
| Abbvie INC. | $70.36 | 2022-2023 | |
| Dexcom, INC. | $59.80 | 2022-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.56 | 2019-2023 | Trulance, Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $51.02 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $37.76 | 2019 | |
| Exact Sciences Corporation | $37.38 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $36.28 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $36.17 | 2019 | |
| Glaxosmithkline, LLC. | $28.60 | 2022-2023 | Bexsero, Rotarix, Menveo |
| Novartis Pharmaceuticals Corporation | $28.20 | 2023 | |
| Genentech USA, INC. | $27.08 | 2019-2020 | |
| Abbott Laboratories | $24.79 | 2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $21.21 | 2023 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $19.65 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.00 | 2019 | |
| Merck Sharp & Dohme LLC | $13.82 | 2020 | |
| Horizon Therapeutics Plc | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.